Junan Guo, Ph.D. has been appointed senior director, analytical and quality services, AMRI. Dr. Guo replaces Dr. Steven Hagen, who was promoted to vice president of pharmaceutical development and manufacturing in September 2008.

Dr. Guo will oversee all domestic analytical chemistry, preformulation and formulation, quality assurance and regulatory affairs efforts, including support related to early stage discovery and preclinical development and the manufacturing of clinical trial materials, intermediates, and commercial APIs. This includes developing analytical methods to test the purity of clinical trial candidates and commercial products manufactured at AMRI. He will lead a team of more than 100 scientists and quality professionals, and will work closely with customers.

Prior to joining the company, Dr. Guo was director, analytical development at Patheon, where he managed the scientific staff responsible for supporting contract dosage form development and manufacturing services. He began his tenure at Patheon in 1999 as the supervisor of analytical development. Prior to Patheon, he worked at Genpharm, Inc. in Toronto, Canada in the areas of analytical R&D and technology transfer.

Dr. Hagen, commented, “We are pleased that Dr. Guo is joining our team as he has considerable CRO experience in pharmaceutical development and he is also trained in Lean Six Sigma techniques. These experiences will greatly aid our expansion plans and efficiency efforts across the AMRI development and manufacturing spectrum.”